Pegenzileukin clinical trials
Also written THOR-707 and SAR444245.
- studies test it
- 7
- open now
- 0
- in phase 3
- 0
- first study started
- 2019
How each study uses pegenzileukin is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
7 studies that test it; most in 2021 (5)
| Year | Studies |
|---|---|
| 2019 | 1 |
| 2021 | 5 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 6 · Other 1
Sanofi (5) · Synthorx, Inc, a Sanofi company (1) · M.D. Anderson Cancer Center (1)
Studies
Open first, then newest update. How each study uses pegenzileukin is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 7
- A Study of SAR444245 Combined With Cemiplimab for the Treatment of Participants With Various Advanced Skin Cancers (Pegathor Skin 201)TerminatedPhase 1/2SanofiNCT04913220Written as THOR-707
- A Study of SAR444245 With or Without Other Anticancer Therapies for the Treatment of Adults and Adolescents With Relapsed or Refractory B Cell Lymphoma (Master Protocol) [Pegathor Lymphoma 205]TerminatedPhase 2SanofiNCT05179603Written as THOR-707
- A Study Evaluating Safety and Therapeutic Activity of THOR-707 in Adult Subjects With Advanced or Metastatic Solid Tumors (THOR-707-101)TerminatedPhase 1/2Synthorx, Inc, a Sanofi companyNCT04009681Written as THOR-707
- A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Lung Cancer or Mesothelioma (Pegathor Lung 202)TerminatedPhase 2SanofiNCT04914897Written as THOR-707
- A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With Gastrointestinal Cancer (Master Protocol) (Pegathor Gastrointestinal 203)CompletedPhase 2SanofiNCT05104567Written as THOR-707
- A Study of SAR444245 Combined With Other Anticancer Therapies for the Treatment of Participants With HNSCC (Master Protocol) (Pegathor Head and Neck 204)TerminatedPhase 2SanofiNCT05061420Written as SAR444245 (Thor-707)
- Phase 2 Study of Neoadjuvant SAR444245 Plus Cemiplimab in HPV Related Oropharynx Squamous Cell CarcinomaWithdrawnPhase 2M.D. Anderson Cancer CenterNCT05535023Written as SAR444245
Given beside what is tested · 1 — pegenzileukin is usual care or a partner of the new treatment
Codes
What other systems call pegenzileukin · ClinicalTrials.gg INT014254
- UNII (FDA) 10WR240QN7PEGENZILEUKINOne source FDA
- NCI Thesaurus C162645PegenzileukinOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 10WR240QN7 | PEGENZILEUKIN | One source FDA |
| NCI Thesaurus | C162645 | Pegenzileukin | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.